Bleeding Events After ST-segment Elevation Myocardial Infarction in Patients Randomized to an All-comer Clinical Trial Compared With Unselected Patients

Golnaz Sadjadieh; Thomas Engstrøm; Dan Eik Høfsten; Steffen Helqvist; Lars Køber; Frants Pedersen; Peter Nørkjær Laursen; Hedvig Bille Andersson; Lars Nepper-Christensen; Peter Clemmensen; Rikke Sørensen; Erik Jørgensen; Kari Saunamäki; Hans-Henrik Tilsted; Henning Kelbæk; Lene Holmvang

doi:10.1016/j.amjcard.2018.07.008

Bleeding Events After ST-segment Elevation Myocardial Infarction in Patients Randomized to an All-comer Clinical Trial Compared With Unselected Patients

Golnaz Sadjadieh, Thomas Engstrøm, Dan Eik Høfsten, Steffen Helqvist, Lars Køber, Frants Pedersen, Peter Nørkjær Laursen, Hedvig Bille Andersson, Lars Nepper-Christensen, Peter Clemmensen, Rikke Sørensen, Erik Jørgensen, Kari Saunamäki, Hans-Henrik Tilsted, Henning Kelbæk, Lene Holmvang

Department of Clinical Medicine

3 Citations (Scopus)

Abstract

Most studies reporting bleedings in patients with ST-segment elevation myocardial infarction (STEMI) are reports from clinical trials, which may be unrepresentative of incidences in real-life. In this study, we investigated 1-year bleeding and mortality incidences in an unselected STEMI population, and compared participants with nonparticipants of a randomized all-comer clinical trial (The Third DANish Study of Optimal Acute Treatment of Patients with STEMI (DANAMI-3)). Hospital charts were read and bleedings classified according to thrombolysis in myocardial infarction (TIMI) and Bleeding Academic Research Consortium (BARC) criteria in 2,490 consecutive STEMI patients who underwent primary percutaneous coronary intervention in a single, large, and tertiary heart center. Thrombolysis in myocardial infarction minor and/or major bleeding (TMMB) occurred in 4.4% day 0 to 30 and 2.1% day 31 to 365. DANAMI-3 nonparticipants (n = 887) had significantly higher 30-day bleeding rates than DANAMI-3-participants (n = 1,603) (7.2% vs 2.9%, p <0.0001), but not thereafter (p = 0.8). DANAMI-3 nonparticipation was significantly associated with 30-day TMMB (hazard ratio, 1.8, 95% confidence interval, 1.2 to 2.8, p = 0.007), but this did not persist after adjusting for resuscitated cardiac arrest, Killip-class>2 and anemia. Patients with cardiac arrest, Killip-class>2, and anemia accounted for 70.0% of 30-day TMMBs, and the majority of these patients were DANAMI-3 nonparticipants. TMMB day 0 to 30 was associated with increased 30-day mortality (hazard ratio 3.1, 95% confidence interval 1.9 to 5.2, p <0.0001) but not thereafter (p = 0.9). In conclusion, we found that clinical trial (DANAMI-3) nonparticipants had significantly more TMMBs within 30 days than participants. Patients with resuscitated cardiac arrest, anemia, and Killip-class>2 were accountable for a high rate of TMMBs. Bleeding incidences from clinical trials cannot be translated to an unselected STEMI population.

Original language	English
Journal	The American Journal of Cardiology
Volume	122
Issue number	8
Pages (from-to)	1287-1296
ISSN	0002-9149
DOIs	https://doi.org/10.1016/j.amjcard.2018.07.008
Publication status	Published - 15 Oct 2018

Access to Document

10.1016/j.amjcard.2018.07.008

Cite this

Sadjadieh, G., Engstrøm, T., Høfsten, D. E., Helqvist, S., Køber, L., Pedersen, F., Laursen, P. N., Andersson, H. B., Nepper-Christensen, L., Clemmensen, P., Sørensen, R., Jørgensen, E., Saunamäki, K., Tilsted, H.-H., Kelbæk, H., & Holmvang, L. (2018). Bleeding Events After ST-segment Elevation Myocardial Infarction in Patients Randomized to an All-comer Clinical Trial Compared With Unselected Patients. The American Journal of Cardiology, 122(8), 1287-1296. https://doi.org/10.1016/j.amjcard.2018.07.008

Bleeding Events After ST-segment Elevation Myocardial Infarction in Patients Randomized to an All-comer Clinical Trial Compared With Unselected Patients. / Sadjadieh, Golnaz; Engstrøm, Thomas; Høfsten, Dan Eik et al.
In: The American Journal of Cardiology, Vol. 122, No. 8, 15.10.2018, p. 1287-1296.

Research output: Contribution to journal › Journal article › Research › peer-review

Sadjadieh, G, Engstrøm, T, Høfsten, DE, Helqvist, S, Køber, L, Pedersen, F, Laursen, PN, Andersson, HB, Nepper-Christensen, L, Clemmensen, P, Sørensen, R, Jørgensen, E, Saunamäki, K, Tilsted, H-H, Kelbæk, H & Holmvang, L 2018, 'Bleeding Events After ST-segment Elevation Myocardial Infarction in Patients Randomized to an All-comer Clinical Trial Compared With Unselected Patients', The American Journal of Cardiology, vol. 122, no. 8, pp. 1287-1296. https://doi.org/10.1016/j.amjcard.2018.07.008

@article{5d73ebd1490c4a64a6daeb085f3a3aec,

title = "Bleeding Events After ST-segment Elevation Myocardial Infarction in Patients Randomized to an All-comer Clinical Trial Compared With Unselected Patients",

abstract = "Most studies reporting bleedings in patients with ST-segment elevation myocardial infarction (STEMI) are reports from clinical trials, which may be unrepresentative of incidences in real-life. In this study, we investigated 1-year bleeding and mortality incidences in an unselected STEMI population, and compared participants with nonparticipants of a randomized all-comer clinical trial (The Third DANish Study of Optimal Acute Treatment of Patients with STEMI (DANAMI-3)). Hospital charts were read and bleedings classified according to thrombolysis in myocardial infarction (TIMI) and Bleeding Academic Research Consortium (BARC) criteria in 2,490 consecutive STEMI patients who underwent primary percutaneous coronary intervention in a single, large, and tertiary heart center. Thrombolysis in myocardial infarction minor and/or major bleeding (TMMB) occurred in 4.4% day 0 to 30 and 2.1% day 31 to 365. DANAMI-3 nonparticipants (n = 887) had significantly higher 30-day bleeding rates than DANAMI-3-participants (n = 1,603) (7.2% vs 2.9%, p <0.0001), but not thereafter (p = 0.8). DANAMI-3 nonparticipation was significantly associated with 30-day TMMB (hazard ratio, 1.8, 95% confidence interval, 1.2 to 2.8, p = 0.007), but this did not persist after adjusting for resuscitated cardiac arrest, Killip-class>2 and anemia. Patients with cardiac arrest, Killip-class>2, and anemia accounted for 70.0% of 30-day TMMBs, and the majority of these patients were DANAMI-3 nonparticipants. TMMB day 0 to 30 was associated with increased 30-day mortality (hazard ratio 3.1, 95% confidence interval 1.9 to 5.2, p <0.0001) but not thereafter (p = 0.9). In conclusion, we found that clinical trial (DANAMI-3) nonparticipants had significantly more TMMBs within 30 days than participants. Patients with resuscitated cardiac arrest, anemia, and Killip-class>2 were accountable for a high rate of TMMBs. Bleeding incidences from clinical trials cannot be translated to an unselected STEMI population.",

author = "Golnaz Sadjadieh and Thomas Engstr{\o}m and H{\o}fsten, {Dan Eik} and Steffen Helqvist and Lars K{\o}ber and Frants Pedersen and Laursen, {Peter N{\o}rkj{\ae}r} and Andersson, {Hedvig Bille} and Lars Nepper-Christensen and Peter Clemmensen and Rikke S{\o}rensen and Erik J{\o}rgensen and Kari Saunam{\"a}ki and Hans-Henrik Tilsted and Henning Kelb{\ae}k and Lene Holmvang",

note = "Copyright {\textcopyright} 2018. Published by Elsevier Inc.",

year = "2018",

month = oct,

day = "15",

doi = "10.1016/j.amjcard.2018.07.008",

language = "English",

volume = "122",

pages = "1287--1296",

journal = "The American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - Bleeding Events After ST-segment Elevation Myocardial Infarction in Patients Randomized to an All-comer Clinical Trial Compared With Unselected Patients

AU - Sadjadieh, Golnaz

AU - Engstrøm, Thomas

AU - Høfsten, Dan Eik

AU - Helqvist, Steffen

AU - Køber, Lars

AU - Pedersen, Frants

AU - Laursen, Peter Nørkjær

AU - Andersson, Hedvig Bille

AU - Nepper-Christensen, Lars

AU - Clemmensen, Peter

AU - Sørensen, Rikke

AU - Jørgensen, Erik

AU - Saunamäki, Kari

AU - Tilsted, Hans-Henrik

AU - Kelbæk, Henning

AU - Holmvang, Lene

PY - 2018/10/15

Y1 - 2018/10/15

N2 - Most studies reporting bleedings in patients with ST-segment elevation myocardial infarction (STEMI) are reports from clinical trials, which may be unrepresentative of incidences in real-life. In this study, we investigated 1-year bleeding and mortality incidences in an unselected STEMI population, and compared participants with nonparticipants of a randomized all-comer clinical trial (The Third DANish Study of Optimal Acute Treatment of Patients with STEMI (DANAMI-3)). Hospital charts were read and bleedings classified according to thrombolysis in myocardial infarction (TIMI) and Bleeding Academic Research Consortium (BARC) criteria in 2,490 consecutive STEMI patients who underwent primary percutaneous coronary intervention in a single, large, and tertiary heart center. Thrombolysis in myocardial infarction minor and/or major bleeding (TMMB) occurred in 4.4% day 0 to 30 and 2.1% day 31 to 365. DANAMI-3 nonparticipants (n = 887) had significantly higher 30-day bleeding rates than DANAMI-3-participants (n = 1,603) (7.2% vs 2.9%, p <0.0001), but not thereafter (p = 0.8). DANAMI-3 nonparticipation was significantly associated with 30-day TMMB (hazard ratio, 1.8, 95% confidence interval, 1.2 to 2.8, p = 0.007), but this did not persist after adjusting for resuscitated cardiac arrest, Killip-class>2 and anemia. Patients with cardiac arrest, Killip-class>2, and anemia accounted for 70.0% of 30-day TMMBs, and the majority of these patients were DANAMI-3 nonparticipants. TMMB day 0 to 30 was associated with increased 30-day mortality (hazard ratio 3.1, 95% confidence interval 1.9 to 5.2, p <0.0001) but not thereafter (p = 0.9). In conclusion, we found that clinical trial (DANAMI-3) nonparticipants had significantly more TMMBs within 30 days than participants. Patients with resuscitated cardiac arrest, anemia, and Killip-class>2 were accountable for a high rate of TMMBs. Bleeding incidences from clinical trials cannot be translated to an unselected STEMI population.

AB - Most studies reporting bleedings in patients with ST-segment elevation myocardial infarction (STEMI) are reports from clinical trials, which may be unrepresentative of incidences in real-life. In this study, we investigated 1-year bleeding and mortality incidences in an unselected STEMI population, and compared participants with nonparticipants of a randomized all-comer clinical trial (The Third DANish Study of Optimal Acute Treatment of Patients with STEMI (DANAMI-3)). Hospital charts were read and bleedings classified according to thrombolysis in myocardial infarction (TIMI) and Bleeding Academic Research Consortium (BARC) criteria in 2,490 consecutive STEMI patients who underwent primary percutaneous coronary intervention in a single, large, and tertiary heart center. Thrombolysis in myocardial infarction minor and/or major bleeding (TMMB) occurred in 4.4% day 0 to 30 and 2.1% day 31 to 365. DANAMI-3 nonparticipants (n = 887) had significantly higher 30-day bleeding rates than DANAMI-3-participants (n = 1,603) (7.2% vs 2.9%, p <0.0001), but not thereafter (p = 0.8). DANAMI-3 nonparticipation was significantly associated with 30-day TMMB (hazard ratio, 1.8, 95% confidence interval, 1.2 to 2.8, p = 0.007), but this did not persist after adjusting for resuscitated cardiac arrest, Killip-class>2 and anemia. Patients with cardiac arrest, Killip-class>2, and anemia accounted for 70.0% of 30-day TMMBs, and the majority of these patients were DANAMI-3 nonparticipants. TMMB day 0 to 30 was associated with increased 30-day mortality (hazard ratio 3.1, 95% confidence interval 1.9 to 5.2, p <0.0001) but not thereafter (p = 0.9). In conclusion, we found that clinical trial (DANAMI-3) nonparticipants had significantly more TMMBs within 30 days than participants. Patients with resuscitated cardiac arrest, anemia, and Killip-class>2 were accountable for a high rate of TMMBs. Bleeding incidences from clinical trials cannot be translated to an unselected STEMI population.

U2 - 10.1016/j.amjcard.2018.07.008

DO - 10.1016/j.amjcard.2018.07.008

M3 - Journal article

C2 - 30115422

SN - 0002-9149

VL - 122

SP - 1287

EP - 1296

JO - The American Journal of Cardiology

JF - The American Journal of Cardiology

IS - 8

ER -

Bleeding Events After ST-segment Elevation Myocardial Infarction in Patients Randomized to an All-comer Clinical Trial Compared With Unselected Patients

Abstract

Access to Document

Fingerprint

Cite this